2013-02-06 22:16:20 -
CONSHOHOCKEN, PA -- (Marketwire) -- 02/06/13 -- NuPathe Inc. : ctt.marketwire.com/?release=982904&id=2583811&type=1& ..
(NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that Armando Anido : ctt.marketwire.com/?release=982904&id=2583814&type=1& ..
, chief executive officer, will present a company overview at the Leerink Swann 2013 Global Healthcare Conference on Wednesday, February 13, 2013, at 2:30 p.m. EST. The conference is being held at the Waldorf Astoria in New York, NY.
A live audio webcast of the presentation will be available via the "Investor Relations" page of the NuPathe website, www.nupathe.com : ctt.marketwire.com/?release=982904&id=2583817&type=1& ..
. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on NuPathe's website for 90 days following the presentation.
NuPathe Inc. is a specialty pharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, Zecuity : ctt.marketwire.com/?release=982904&id=2583820&type=1& ..
(sumatriptan iontophoretic transdermal system) has been approved by the FDA for the acute treatment of migraine with or without aura in adults. Zecuity is expected to be available by prescription in the fourth quarter of 2013. In addition to Zecuity, NuPathe has two proprietary product candidates based on its LAD, or Long-Acting Delivery, biodegradable implant technology that allows delivery of therapeutic levels of medication over a period of months with a single dose. NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist, ropinirole, and is being developed to provide up to two months of continuous delivery. NP202, for the long-term treatment of schizophrenia and bipolar disorder, is being developed to address the long-standing problem of patient noncompliance by providing three months of continuous delivery of risperidone, an atypical antipsychotic. NuPathe is actively seeking partnerships to maximize the commercial potential for Zecuity and its other product candidates in the U.S. and territories throughout the world.
For more information about NuPathe, please visit our website and our blog at www.nupathe.com : ctt.marketwire.com/?release=982904&id=2583823&type=1& ..
. You can also follow us on StockTwits (stocktwits.nupathe.com), Twitter (twitter.nupathe.com), SlideShare (slideshare.nupathe.com) and LinkedIn (linkedin.nupathe.com).
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to: the potential benefits of, and commercial opportunity for, Zecuity and NuPathe's other product candidates; partnering plans for Zecuity and NuPathe's other product candidates; the timing of the expected launch and availability of Zecuity; and other statements relating to NuPathe's plans, objectives, expectations and beliefs regarding its future operations, performance, financial condition and other future events. Forward-looking statements are based upon management's current expectations and beliefs and are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results and events to differ materially from those indicated herein including, among others: NuPathe's ability to obtain sufficient capital to launch Zecuity; NuPathe's ability to obtain commercial and development partners for Zecuity and its other product candidates; NuPathe's reliance on third parties to manufacture Zecuity; NuPathe's ability to establish and effectively manage its supply chain; NuPathe's ability to establish effective marketing and sales capabilities; market acceptance among physicians and patients and the availability of adequate reimbursement from third party payors for Zecuity; and the risks, uncertainties and other factors discussed in NuPathe's Annual Report on Form 10-K for the year ended December 31, 2010 and Quarterly Report on Form on Form 10-Q for the quarter ended September 30, 2012 under the caption "Risk Factors" and elsewhere in such reports, which are available on NuPathe's website at www.nupathe.com : ctt.marketwire.com/?release=763099&id=377803&type=1& ..
in the "Investor Relations -- SEC Filings" section. While NuPathe may update certain forward-looking statements from time to time, it specifically disclaims any obligation to do so, whether as a result of new information, future developments or otherwise. You are cautioned not to place undue reliance on any forward-looking statements.
Westwicke Partners, LLC
Keith A. Goldan
Vice President & Chief Financial Officer